Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling
about
The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymeraseStructure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosaCrystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2The 1.8 A Cholix Toxin Crystal Structure in Complex with NAD+ and Evidence for a New Kinetic ModelStructural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1Crystal Structure of Human ADP-ribose Transferase ARTD15/PARP16 Reveals a Novel Putative Regulatory DomainInhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasitePoly(ADP-ribosyl)ation reactions in the regulation of nuclear functionsB-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity.No Silver Bullet - Canonical Poly(ADP-Ribose) Polymerases (PARPs) Are No Universal Factors of Abiotic and Biotic Stress Resistance of Arabidopsis thaliana.Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral protein.Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.Identifying Family-Member-Specific Targets of Mono-ARTDs by Using a Chemical Genetics Approach.New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases.From laptop to benchtop to bedside: structure-based drug design on protein targets.PARP1 ADP-ribosylates lysine residues of the core histone tails.Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiencyPoly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.PARP1 Inhibitors: antitumor drug design.Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cellsPredicting enhanced cell killing through PARP inhibition.Disrupted ADP-ribose metabolism with nuclear Poly (ADP-ribose) accumulation leads to different cell death pathways in presence of hydrogen peroxide in procyclic Trypanosoma brucei.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondInhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced CytotoxicityExpression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcomeStructural Implications for Selective Targeting of PARPs.Conformational activation of poly(ADP-ribose) polymerase-1 upon DNA binding revealed by small-angle X-ray scattering.Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging.Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling.PARP inhibitors for anticancer therapy.Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.The rise and fall of poly(ADP-ribose): An enzymatic perspective.Role of PARP-1 in prostate cancer.Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
P2860
Q22010521-56BD1D1A-A5D4-443E-BB19-1A8A0735BCEBQ24528153-6797848D-9404-4CAD-8D31-DB4BD238D004Q27643011-348B031A-7102-4CF3-8DB9-93A4CD10ADF0Q27678743-CCF22AF7-590D-4ACE-A7BB-64E24CB718F3Q27679074-6512953B-D776-4FDA-9934-F847F20563D0Q27679467-603D3133-A603-4C55-8A13-403CBEC5D54BQ28483989-6074EDC1-2E1F-4BE1-ADB9-35FD28C8630FQ29617672-C301773C-FEAB-424B-8275-60D8881F6393Q29977777-D61CC1F1-0F06-43BA-9DCB-A56ECF26BE89Q30313407-DDD1ABA4-036F-42BF-A340-3AC0472D3D45Q33316824-B9A45D74-F770-48D5-9A09-4FC006B25C43Q33607384-810A169B-7213-4E3B-807A-1A3776468E88Q33614632-C5B1B168-8F08-4D3B-A83F-A66A7343D0C2Q33652648-37A3EB06-1566-4071-83A1-E69E129A94D3Q34042969-FEE2B626-6CF0-4936-8CB1-C489DD686461Q34153589-92BD43FF-3B32-439E-9881-4DB8776D867FQ34246667-C6577DA1-936B-4955-BFB0-3AB5CC8F9FE3Q34299288-D584F633-8318-49BE-A7DF-7C9BB795E15FQ35876447-406CDC1A-792D-4B2D-B361-3C2DF4B94760Q36111918-B6BF661F-CD18-4225-9FA2-68E8B8959492Q36175159-E1EF91E8-9CD4-4A91-B40B-96D86396A02AQ36251670-64748058-4DE4-45B0-B07A-FECD55A86CC6Q36553266-1EDA610E-B7AE-4368-A49E-D1110B94AAE2Q36725115-144E756B-70D1-4764-95AA-BBAB4F8C5372Q36853236-4A2613C0-10B8-42A8-A95D-B74FE1219047Q37122690-B7755B7D-050F-468D-8123-A90D20BBF690Q37205681-1935464A-9EF2-4280-9B01-F2BAE9F2025BQ37308690-EED47887-3E63-4271-8941-C410CD5910ACQ37405386-F41D1BFD-1473-44F0-84FB-CAEC9F08B52FQ37678007-1022B6D8-BF7A-4877-A33A-D6F6F074771CQ37693027-F3EF93EE-08AC-45F3-8F54-5FD31E747520Q37774359-7036BA21-B2C1-4B39-8D50-EBA5E5D9D03DQ38075305-6B276009-122B-46C3-9F54-BD022A9E0E19Q38086332-B1AA72FD-4EDD-41D1-8B43-A782DF1DDAC4Q38180762-5682CB76-F1D7-4FEA-9791-D8F84C32B07BQ38469746-81F03341-E207-43C6-B2A3-7C7E1112F585Q38473760-9604140E-D0E4-4A78-8C9D-FDDB7D7BD558Q38526322-75FFCEB8-06CE-4895-956E-B80834B80943Q38596368-CD83C855-8F37-4F5F-A6DA-8631E532073CQ39007680-26828E8D-2E77-44C0-8316-59BC173C6F5F
P2860
Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
name
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@ast
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@en
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@nl
type
label
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@ast
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@en
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@nl
prefLabel
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@ast
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@en
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@nl
P2093
P3181
P356
P1433
P1476
Inhibitor and NAD+ binding to ...... ructures and homology modeling
@en
P2093
P304
P3181
P356
10.1021/BI972383S
P407
P577
1998-03-17T00:00:00Z